Callan Family Office LLC Invests $543,000 in West Pharmaceutical Services, Inc. (NYSE:WST)

Callan Family Office LLC bought a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,659 shares of the medical instruments supplier’s stock, valued at approximately $543,000.

Other large investors have also made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in shares of West Pharmaceutical Services by 6.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,449,811 shares of the medical instruments supplier’s stock worth $1,130,020,000 after acquiring an additional 203,198 shares during the period. State Street Corp raised its stake in West Pharmaceutical Services by 0.3% during the third quarter. State Street Corp now owns 3,214,448 shares of the medical instruments supplier’s stock worth $964,850,000 after acquiring an additional 10,060 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of West Pharmaceutical Services by 0.7% during the third quarter. Geode Capital Management LLC now owns 1,740,183 shares of the medical instruments supplier’s stock valued at $520,569,000 after acquiring an additional 12,850 shares during the period. Van ECK Associates Corp lifted its holdings in West Pharmaceutical Services by 5,074.0% during the 4th quarter. Van ECK Associates Corp now owns 689,493 shares of the medical instruments supplier’s stock valued at $225,851,000 after purchasing an additional 676,167 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of West Pharmaceutical Services by 21.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 683,350 shares of the medical instruments supplier’s stock valued at $205,114,000 after acquiring an additional 122,361 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on WST. Bank of America increased their target price on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Citigroup assumed coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price objective on the stock. StockNews.com lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. KeyCorp reduced their price objective on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, Wolfe Research began coverage on West Pharmaceutical Services in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $344.00.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $231.55 on Monday. The firm has a 50-day moving average of $295.38 and a 200-day moving average of $305.86. The company has a market cap of $16.74 billion, a PE ratio of 34.61, a price-to-earnings-growth ratio of 6.74 and a beta of 1.09. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. West Pharmaceutical Services, Inc. has a one year low of $197.01 and a one year high of $400.88.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.07. The firm had revenue of $748.80 million during the quarter, compared to the consensus estimate of $739.59 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. As a group, equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.36%. The ex-dividend date is Wednesday, April 30th. West Pharmaceutical Services’s dividend payout ratio is currently 12.56%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.